Scientific journal highlights study of the DRP tool in cisplatin treatment for patients with lung cancer
Hoersholm, Denmark – March 22, 2018 – Oncology Venture Sweden AB:s (OV:ST) (“Oncology Venture” or “OV”) and Medical Prognosis Institute (MPI.ST) (“Medical Prognosis Institute” or “MPI”) announces positive study results for the diagnostic tool DRP® in lung cancer patients treated with cisplatin. The findings have been published in the scientific journal PLOS ONE under the title “Molecular Prediction of adjuvant cisplatin efficacy in Non-small cell lung cancer – validation in two independent cohorts.” Data from both a prospective randomized clinical trial and a Danish NSCLC patient cohort